All posts by imreal

“Child Mental Health Matters” Infographic Released for World Mental Health Day (October 10)


The “Child Mental Health Matters” Infographic centralizes key statistics for child mental health and raises awareness of “prevention” being a missing link in child mental health solutions.

Because youth mental health has been declared a national emergency, and US Surgeon General Vivek Murthy has been in the media recently raising awareness of this issue, Adventures in Wisdom has created and released a free infographic called “Child Mental Health Matters”.

The infographic centralizes key statistics for child mental health and raises awareness of “prevention” being a missing link in child mental health solutions.

The infographic is available for download:

The statistics – sourced from the Center of Disease Control, Department of Health and Human Services, and Children’s Hospital Association – are alarming and include that self-injury and suicide in kids 5-17 years old increased 45% in the first half of 2021.

“When three pediatric organizations declared youth mental health a national emergency and called for ‘strategies to meet these challenges… across the continuum of mental health promotion, prevention, and treatment’, we made it our mission to raise awareness of life coaching for kids as part of the mental health solution, because most people aren’t aware of it,” said Renaye Thornborrow, founder of Adventures in Wisdom, a company that has certified hundreds of life coaches for kids in over 30 countries since 2013.

Renaye adds, “Life coaching sits on the prevention side of the continuum – helping kids develop mindset skills for resilience, self-esteem, confidence, self-leadership, achievement, and happiness so that kids can manage the ups and downs of growing up and thrive in life. Life coaching isn’t counseling and it isn’t therapy. Life coaching for kids is mindset training and helps children develop mental fitness before counseling is needed. Parents need to know that there is additional support available for their children.”

To learn more about how life coaching for kids is transforming the lives of children, get this FREE Special Report:How Life Coaching for Kids is Transforming Children’s Lives.

###

About Renaye Thornborrow and Adventures in Wisdom Inc.

Renaye Thornborrow is leading a worldwide movement to bring life coaching to kids. Since 2013, her company, Adventures in Wisdom Inc., has certified hundreds of coaches in over 30 countries, helping them create a business they love as a life coach for kids while empowering children around the world. For Renaye, motherhood was the catalyst for turning her lifelong passion for personal development into a comprehensive and effective story-based coaching curriculum to bring life coaching to kids. Life coaching is a game changer for children as they learn how to build confidence, resilience, and mindset skills for life; and it is a game changer for coaches as they increase their impact and income while doing their work in the world serving kids. Renaye is the founder and CEO of Adventures in Wisdom and author of The Adventures in Wisdom Life Coaching Program for Kids Curriculum™. She’s a member of the International Coaches Federation, and former 3-year board member for the Association of Coach Training Organizations (ACTO). To learn more, visit https://www.adventuresinwisdom.com, call 512-222-6659, or send email to renaye@adventuresinwisdom.com

Share article on social media or email:

uMotif to Showcase How Transformative eCOA/ePRO Technology Enables Faster, More Engaging Trials and Real-World Studies at Premier Pharma and Biotech Industry Events


News Image

uMotif will share its unique perspective on how pharma and biotech can and must adopt market-tested eCOA/ePRO solutions that engage patients to run better trials and real-world studies at top industry events during Q4.

uMotif, one of the clinical research technology market’s fastest growing companies, will share its unique perspective on how pharma and biotech can and must adopt market-tested eCOA/ePRO solutions that engage patients to run better trials and real-world studies at top industry events during Q4…

October

—Pharma 2022, Nice Acropolis Convention Center Exhibit in Nice, France, October 11-13

—North Carolina Biosciences Organization Annual Meeting, NC Biotech Center in Research Triangle Park, NC, October 12

—Outsourcing in Clinical Trials New England, Westin Boston Seaport District Hotel in Boston, MA, October 12-13

November

—ISPOR Europe, Austria Center Vienna in Vienna, Austria and online, November 6-9

—Data Management Biomedical, Cité Universitaire Internationale in Paris, France, November 14

—CNS Summit 2022, Boca Raton Hotel, in Boca Raton, FL, November 17-20, (Sponsor) – uMotif CEO Steve Rosenberg (LinkedIn) will lead a panel discussion on the path to true patient engagement

—North Carolina Biosciences Organization Clinical Trials Forum, NC Biotech Center in Research Triangle Park, NC, November 29

December

—IDF Lisbon, Centro de Congressos de Lisboa CCL, in Lisbon, Spain and online, December 5-8 – On December 6, uMotif Chief Patient Officer and Co-Founder Bruce Hellman (LinkedIn) will participate in a panel discussion on PROMS in diabetes care, in the Healthcare Track

To arrange a personal meeting with a uMotif executive at any of these events, email mailto:contact@umotif.com [contact@umotif.com __title__ null]

About uMotif

The uMotif eCOA/ePRO platform delivers faster, quality clinical trials by putting participants at the core of research. uMotif’s configurable, modular and customizable eClinical cloud native platform powers site-based to fully decentralized clinical, real world, and post marketing research. Find out why global pharma companies, biotechs, CROs, and academic institutions rely on uMotif to capture unprecedented volumes of high quality eCOA/ePRO, symptom and wearable device data at http://www.umotif.com.

Share article on social media or email:

On World Mental Health Day (October 10), Adventures in Wisdom Fills a Gap in Child Mental Health Solutions


Life coaching isn’t therapy and it isn’t counseling. It’s mindset skills training that helps children learn how to navigate the ups and downs of growing up and achieve their goals, so that they are confident and prepared to thrive in life.

Because October 10th is World Mental Health Day, Adventures in Wisdom is raising awareness of a gap in child mental health solutions – prevention. Life Coaching for Kids is a prevention strategy that most people aren’t aware of – helping children develop mindset skills for resilience, confidence, self-esteem, self-leadership, and achievement so that they can develop an empowered way of thinking at a young age.

“Life coaching isn’t therapy and it isn’t counseling,” shared Renaye Thornborrow, founder of Adventures in Wisdom, a company that has certified hundreds of life coaches for kids in over 30 countries since 2013. “It is mindset skills training that helps children learn how to navigate the ups and downs of growing up and achieve their goals, so that they are confident and prepared to thrive in life.”

With cases of self-injury and suicide up 45% amongst children ages 5-17 in the first half of 2021, there has never been a more urgent time to support children in developing their mental fitness early in life.*

“Our WISDOM Coaches have seen an increase in parents wanting to support their children in rebuilding their confidence and their self-esteem after the pandemic,” shared Thornborrow. “Lack of motivation and managing change have also been common themes. I’m so proud of the positive impact our coaches are having on children and their families – children who were sitting on the sidelines are reengaging in life and feeling happy again.”

To see real-life success stories of how WISDOM Coaches have supported children during and after the pandemic: click here for 5 success stories.

To learn more about how life coaching for kids is filling the gap in children’s mental health: click here for the online version of “The Ultimate Guide to Life Coaching for Kids”.

*https://www.childrenshospitals.org/news/newsroom/2021/12/sound-the-alarm-for-kids-raises-awareness

About Renaye Thornborrow and Adventures in Wisdom Inc.

Renaye Thornborrow is leading a worldwide movement to bring life coaching to kids. Since 2013, her company, Adventures in Wisdom Inc., has certified hundreds of coaches in over 30 countries, helping them create a business they love as a life coach for kids while empowering children around the world. For Renaye, motherhood was the catalyst for turning her lifelong passion for personal development into a comprehensive and effective story-based coaching curriculum to bring life coaching to kids. Life coaching is a game changer for children as they learn how to build confidence, resilience, and mindset skills for life; and it is a game changer for coaches as they increase their impact and income while doing their work in the world serving kids. Renaye is the founder and CEO of Adventures in Wisdom and author of The Adventures in Wisdom Life Coaching Program for Kids Curriculum™. Adventures in Wisdom is an ICF CCE (International Coaching Federation Continuing Coach Education) provider. To learn more, visit https://www.adventuresinwisdom.com, call 512-222-6659, or send email to renaye@adventuresinwisdom.com

Share article on social media or email:

Los Angeles’ Leading Expert, Dr. David G. Davtyan, Recognized as a 2022 Top Patient Rated LA Bariatric Weight Loss Surgeon


News Image

“Being recognized with this award from Find Local Doctors is such an honor. I strive to achieve the best possible outcomes and results, creating positive changes in the lives of my patients,” says Dr. David Davtyan.

Board-certified in surgery and bariatric medicine, Dr. David G. Davtyan is one of the most respected bariatric weight loss surgeon s that the Los Angeles area has to offer. He has been selected as a 2022 Top Patient Rated LA Bariatric Surgeon as a result of five-star ratings and positive reviews from patients through reputable online sources. Find Local Doctors is a user-friendly online directory, that helps consumers connect with skilled physicians in their area. Many satisfied patients have commented on the unmatched surgical skill, attention to detail and ability to put them at ease as they embark on the exciting journey to lose weight and reclaim their health.

Dr. Davtyan is a well-recognized, highly respected weight loss surgeon with over 28 years of experience and has treated thousands of patients with successful results. At his clinic, The Weight Loss Surgery Center of Los Angeles, his team offers patients comprehensive medical and surgical weight loss solutions. His expertise helps patients overcome weight loss challenges once and for all, reclaiming control of their bodies and health. At The Weight Loss Surgery Center of Los Angeles, he offers a wide range of medical endoscopic, surgical and minimally invasive weight loss procedures with excellent outcomes. He provides patients with many solutions to attain weight loss, including bariatric surgery options, gastric sleeve, gastric balloon, and LAP-BAND solutions for patients wanting to achieve significant weight loss.

“Being recognized with this award from Find Local Doctors is such an honor. I strive to achieve the best possible outcomes and results, creating positive changes in the lives of my patients,” says Dr. David Davtyan.

More about Dr. David Davtyan:

Dr. David Davtyan achieved his medical degree from UCLA’s School of Medicine, where he was trained to treat extremely difficult and metastatic cancer cases. For over ten years, he devoted his career to helping patients beat cancer – until he discovered bariatric surgery. The success he observed from the LAP-BAND procedure prompted him to focus his practice entirely on performing weight loss procedures to transform his patients’ lives. He went on to study bariatric surgery in Belgium, where the LAP-BAND was first introduced and became one of the first surgeons in the United States to offer the procedure once it achieved FDA approval in April of 2001. Dr. Davtyan and his team offer top-quality weight loss surgery (bariatric surgery) in Los Angeles, Orange County and the Inland Empire, offering a spectrum of medical endoscopic, surgical and minimally invasive weight loss procedures with excellent outcomes. For more information please call 877-923-7546 or visit http://www.weightlosssurgeryla.com.

Share article on social media or email:

Captiva Spine announces an exclusive strategic partnership with REMEX Medical for Spine Navigation and Robotics, adding to their expanding product portfolio


Spine Navigation and Robotics: Exclusive Strategic Partnership

We plan to have a technically advanced navigation platform to improve spine procedural efficiency and be economically feasible for the growing number of ASCs and specialty hospitals throughout the United States.

Captiva Spine is a medical device organization located in Jupiter, Florida, dedicated to delivering smart, elegant, and intuitive spinal fusion solutions. They announced today its long-term exclusive strategic partnership with REMEX Medical, a developer of advanced navigation and robotics technologies located in Taichung, Taiwan; for spine navigation with future developments in practical robotic solutions.

Captiva Spine looks forward to serving the substantial need and demand for both navigation and surgical robots for spinal applications. For underserved hospitals and Ambulatory Surgery Centers (ASCs) throughout the U.S., the technology will serve as a platform to expand the company’s products and services with enhanced enabling technology to support MIS technology; specifically starting with their CapLOX Pedicle Screws, TowerLOX-EXT MIS Extended Tab Pedicle Screws, and TransFasten Posterior SI joint fusion system.

Nelson Lin, CEO of REMEX Medical, said, “we are very pleased to enter the US marketplace with our new strategic partner, Captiva Spine. We share an enthusiasm and commitment to providing ongoing advancements for the betterment of spine care. REMEX has been researching and developing this platform for eight years with proven clinical performance.”

The navigation system has 510(k) clearance from the FDA (U. S. Food and Drug Administration) and is available for commercial use. The navigation unit is a small on-site unit for more facilities looking to take advantage of the benefits of readily available, easy-to-use spine navigation. This model offers physicians, orthopedics, and neurosurgeons easy-to-use, cutting-edge technology to pre-plan and visualize their surgical approach. This platform utilizes preoperative CT scans and rapid intraoperative registration for accurate real-time 3D navigation with limited radiation exposure to staff and patients.

“This platform for navigation helps fulfill our commitment to being a clinical and economical solution with advanced enabling technology for spine care,” said Dale Mitchell, President of Captiva Spine. “We plan to have a technically advanced navigation platform to improve spine procedural efficiency and be economically feasible for the growing number of ASCs and specialty hospitals throughout the United States,” Mitchell continued.

The spine navigation platform will be demonstrated at Captiva Spine’s booth (#3731) at the 2022 North American Spine Society (NASS) Annual Meeting in Chicago, IL, October 12-14.

Spine Navigation allows surgeons to oversee the precise placement of MIS pedicle screws while situated directly at the operation site, guided by navigation technology. “Our goal is to provide a technology for reproducibility of screw accuracy and placement with higher confidence and safety in difficult areas is also a goal in mind, as well as improving screw insertion times, especially in cases of difficult anatomy,” said Mitchell.

Captiva Spine is planning to expand the system’s capabilities to include robotics. Both platforms are intended to improve the reproducibility and accuracy of applicable procedures to meet the growing demand for enabling solutions worldwide.

Inquiries from physicians and industry professionals looking to incorporate intelligent and innovative technologies into their offerings are always welcome. Captiva Spine can be contacted directly by phone at 561-277-9480.

Discover strength through connections at http://www.captivaspine.com.

About Captiva Spine, Inc.

Captiva Spine is a privately owned medical device organization founded in 2007. Captiva Spine supports spine surgeons, tenured spine distributors, and healthcare facilities. In providing patients with progressive spinal care and an obsessive focus on quality, they strive to create and maintain sincere, honest, collaborative relationships. Valuing their relationships fosters the mutual trust and openness needed for Captiva Spine to be a conduit of high-quality, smart, elegant, and intuitive patient solutions. Captiva Spine operates as a family of industry professionals that take pride in delivering these solutions responsibly and ethically. While never losing sight of what they refer to as the Human Factor, they find joy in their daily lives and serve the needs of their customers with sincere, professional enthusiasm.

Share article on social media or email:

Reverba Celebrates 20 Years of Amplifying Patient Voices


“We’re incredibly proud of what we’ve accomplished over the past twenty years,” said Cheryl Lubbert, CEO and co-founder of Reverba. “

Reverba, a leading global patient engagement company, announces the celebration of its 20th Anniversary. This marks two decades of empowering people to share their health experiences to make an impact for others and help transform the healthcare industry.

Founded in 2002 as Health Advocacy Strategies, Reverba solidified its reputation as a leader in patient centricity and has since evolved to become a new type of global health engagement company that offers purpose-built solutions to support its clients across the biopharmaceutical continuum of clinical development and commercialization.

“We’re incredibly proud of what we’ve accomplished over the past twenty years,” said Cheryl Lubbert, CEO and co-founder of Reverba. “This is an important milestone because it reflects the depth of our experience and how many lives we’ve been able to impact. Our mission to amplify the patient voice to create meaningful change will continue to shape how we grow as an organization and how we guide the biopharmaceutical industry.”

To mark the occasion, Reverba is launching a campaign to underscore how a partnership between patients and biopharmaceutical companies is the best path to a better future for healthcare. 20 Reasons to Believe will highlight ways in which this collaboration benefits everyone and achieves goals that make a lasting impact.

About Reverba:

Reverba is a global patient engagement company that creates transformative tech-enabled solutions to build a bridge between patients and biopharma companies, from clinical development through commercialization. Through its Clinical and Commercial divisions, Reverba creates comprehensive custom patient engagement solutions using its proprietary reverbaBRIDGE™ technology platform and reverbaCONNECT™ foundational services. Reverba infuses compliance throughout all of its technology platforms and patient engagement solutions, maintaining SOC 2, Type II certification for the highest level of security. For more information, visit http://www.reverba.com or contact connect@reverba.com

Share article on social media or email:

Simplicty Latest Album from Chart-Topping, Critically-Acclaimed Composer, Chuck Wild


Chuck Wild launches “Artist Takeover” of Pandora’s Sleep Radio starting Oct. 10

“As many people around the world have difficulty accessing professional help for mental and physical wellness, my hope is that the slow calming Liquid Mind wellness music will help provide an atmosphere of calm and tranquility in our challenging times…”

In honor of World Mental Health Day on October 10, the largest ad-supported audio entertainment streaming service in the U.S., Pandora, is teaming up with Los-Angeles-based composer, producer and Emmy®-nominated songwriter, Chuck Wild (Liquid Mind), to help bring awareness to our world’s growing mental health crises and to provide some essential tools to help manage the stress and anxiety resulting from our fast-paced, high intensity lives.

During the pandemic, Wellness became a fast-growing genre on Pandora as listeners began to achieve better mental health, and Liquid Mind® is the top Wellness artist on Pandora. Wild, whose best-selling, downtempo chill-out Liquid Mind® albums on the Myndstream label consistently top Billboard’s New Age Music charts, is releasing his 18th album exclusively on Pandora for one week starting on October 10th.

Wild will also launch an “Artist Takeover” of Pandora’s Sleep Radio station this week, providing guided meditations and discussing the healing ethos behind Liquid Mind® through a special The Takeover: Liquid Mind station “Mode.” Pandora Modes are a unique feature that lets users customize their Pandora listening experience by choosing from selectable “modes” on their favorite stations to give more control over which songs they hear.

The theme of World Mental Health Day this year is “Mental Health in an Unequal World,” which is fitting since Wild created his music as an antidote to anxiety and stress in the world and to aid his own mental wellness recovery. In fact, Wild created Liquid Mind® as a response to the panic and anxiety he personally experienced during the stressed years of 1987-1990 while composing music for the Emmy-winning TV show Max Headroom® and at the same time living through the trauma of having more than 60 of his friends and associates pass on from HIV/AIDS.

In 2021, New Age Note’s Dyan Garris called Liquid Mind® “the quintessential relaxation experience by the quintessential master of relaxation.”

“Music is a bridge that unites us,” says Wild, “and I’m proud to launch my 18th Liquid Mind album on Pandora’s global platform. As many people around the world have difficulty accessing professional help for mental and physical wellness, my hope is that the slow calming Liquid Mind wellness music will help provide an atmosphere of calm and tranquility in our challenging times, and will be a benefit to all people, no matter who they are or where they live.”

Beginning October 17th, LIQUID MIND XIV: SIMPLICITY will be released on the Myndstream music label and made widely available across all audio streaming platforms and on CD at all participating retailers.

About Myndstream: A music company at the intersection of art and science, creating research-backed compositions designed for health and wellbeing. Aiming to become the most validated and impactful music business in the world, Myndstream draws on its incredible roster of critically acclaimed wellbeing musicians, as well as its extensive expert advisory network, to create the highest quality music-led, wellbeing programs. Drawing on the knowledge of its parent company, the award-winning Cutting Edge Group — the leading independent full-service provider of “music for moments” across the film, television videogames and advertising industries, commercializing the music in such high-profile productions as Bridgerton, Stranger Things, The King’s Speech, Severance and more — Myndstream’s goal is to create engaging soundtracks for all types of mindful environments and activities.

About Pandora: Pandora, a subsidiary of SiriusXM, is the largest ad-supported audio entertainment streaming service in the U.S. Pandora provides consumers a uniquely-personalized music and podcast listening experience with its proprietary Music Genome Project® and Podcast Genome Project® technology. Pandora is also the leading digital audio advertising platform in the U.S. Through its own Pandora service, its AdsWizz platform, and third-party services, such as SoundCloud, the Company connects brands to the largest ad-supported streaming audio marketplace in the country. Pandora is available through its mobile app, the web, and integrations with more than 2,000 connected products.

Share article on social media or email:

VGXI Celebrates the Grand Opening for its New Headquarters and Manufacturing Facility


VGXI Conroe Grand Opening Ribbon Cutting

This new VGXI headquarters is purpose-built to leverage the company’s existing expertise in DNA and RNA manufacturing and greatly expand our capacity to support growing industry demands.

VGXI, Inc., a specialized contract developer and manufacturer (CDMO) of nucleic acid biopharmaceuticals including gene therapies, DNA vaccines, and RNA medicines, celebrated the official grand opening of its new headquarters and manufacturing facility located at Deison Technology Park in Conroe, TX. U.S. Congressman Kevin Brady and the Consul General of the Republic of Korea in Houston Ahn Myung Soo attended the ribbon cutting on October 7, 2022 to recognize this important milestone and VGXI’s contributions to the global pharmaceutical community.

The ribbon cutting was attended by VGXI clients, contractors, and business partners, as well as city of Conroe officials and representatives of the local and Texas biotechnology communities, including Ms. Ann Tanabe, CEO of BioHouston.

“VGXI’s clients and collaborators are developing the next generation of gene therapies and vaccines,” said CEO Young Park. “This new VGXI headquarters is purpose-built to leverage the company’s existing expertise in DNA and RNA manufacturing and greatly expand our capacity to support growing industry demands.”

VGXI has operated as a CDMO since 2003 supporting the development of new cancer therapies, gene and cell therapies, and DNA vaccines for critical emerging diseases including Ebola, MERS, Zika, and COVID-19. With expanded capabilities offered by the 120,000 square-foot Conroe facility, the company is now booking 2023 GMP manufacturing slots at fermentation scales from 10L to 1500L across multiple independent manufacturing trains. Dedicated areas are also available for personalized immunotherapy indications and GMP mRNA production.

ABOUT VGXI, INC.

With over 20 years of experience VGXI, Inc. is a leading provider of plasmid DNA manufacturing and development services. The company has a reputation of success in manufacturing DNA products under cGMP conditions for clinical trials in the US, EU, Asia, Canada, and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and highly experienced development team. VGXI, Inc. is a GeneOne company. To learn more, visit https://www.vgxii.com.

ABOUT GENEONE LIFE SCIENCE

GeneOne Life Science Inc. (“GeneOne” KOSPI: 011000) headquartered in Seoul, South Korea is an international biotechnology company and a leading contract manufacturer of DNA plasmids for use in vaccines, gene therapies, and cell therapies. GeneOne has recently expanded into the manufacture and development of mRNA. GeneOne has maintained a focus on vaccines against emerging infectious diseases to address global needs, including in resource challenged regions. Its small molecule portfolio of immunomodulators address diseases such as prevention of upper respiratory bacterial and viral diseases, and treatment of autoimmune and inflammatory diseases. GeneOne has three products against COVID-19 in clinical development: GLS-5310 DNA vaccine (Phase I/IIa), GLS-1200 nasal spray to prevent COVID-19 infection (Phase II), and GLS-1027 to prevent the inflammation and clinical worsening for those infected with COVID-19 (Phase II).

For more information, visit https://www.genels.com.

CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS

Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of GeneOne stock. It is also important to read the disclosure notice contained in many of the individual GeneOne documents available on the website, as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

Share article on social media or email:

ISPE Announces Leaders from FDA, Pfizer, Takeda, Cognizant, and Gilead to Speak at Annual Meeting & Expo


The International Society for Pharmaceutical Engineering (ISPE) announced seven keynote speakers for the 2022 ISPE Annual Meeting & Expo, taking place 30 October–2 November 2022 in Orlando, Florida, and virtually. This signature event brings together top pharmaceutical industry and regulatory leaders offering compelling presentations and interactive discussions on industry-critical technical developments.

The 2022 ISPE Annual Meeting & Expo features a dynamic line-up of thought-provoking keynote presentations led by some of the most prominent names in the pharmaceutical industry.

Confirmed Keynote Speakers:

Andres Angelani, Senior Vice President, Global Head of Digital Engineering, Cognizant Technology Solutions

Andres Angelani is the Senior Vice President and Global Head of Digital Engineering at Cognizant, a leading provider of information technology, consulting and business process services. He is a proven leader at blending design and engineering disciplines that not only boost business performance, but also help organizations build modern business that can seize the potential of the digital revolution.

Tom Cheslock, Vice President, Hospital Business Unit Global Supply Chain, Pfizer

Tom Cheslock is currently the Vice President, Global Supply Chain of Pfizer’s Hospital Business Unit (HBU), and a member of the Global Supply Chain Leadership Team. He is the primary Pfizer Global Supply (PGS) interface to the Global HBU Commercial Business Unit with accountability for achieving customer service targets including escalation and coordination of supply resolution and optimized inventory targets.

Joydeep Ganguly, Senior Vice President, Corporate Operations, Gilead Sciences Inc.

Joydeep Ganguly is Senior Vice President, Corporate Operations at Gilead Sciences. In his current role, he is accountable for several strategic functions, including corporate engineering and operations; infrastructure and capital planning; sustainability; risk management and resilience; global procurement; and the program management office. Mr. Ganguly also oversees Gilead’s footprint strategy and corporate real estate portfolio.

Julie Kim, President, U.S. Business Unit and U.S. Country Head, Takeda

Julie Kim is President of Takeda’s U.S. Business Unit and U.S. Country Head. Ms. Kim has nearly 30 years of experience in health care, 15 of those in international leadership positions. She joined Takeda in 2019 through the acquisition of Shire, where throughout her time she held many diverse roles with increasing responsibility through her time at Baxter/Baxalta/Shire. In 2020, Ms. Kim was instrumental in bringing together most of the plasma companies to form the CoVIg-19 Plasma Alliance, to develop and manufacture a potential therapy to treat COVID-19.

Michael Kopcha, PhD, RPh, Director, Office of Pharmaceutical Quality, CDER/FDA

Michael Kopcha, PhD, RPh, is the Director of the FDA’s Office of Pharmaceutical Quality (OPQ). This office has over 1,300 staff responsible for assuring the availability of quality medicines for the American public through assessment, inspection, surveillance, research, and policy. Prior to joining the FDA, Dr. Kopcha amassed more than 25 years of experience in major and mid-sized innovator, generic, drug/device, and over-the counter (OTC) pharmaceutical and consumer health companies.

Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research, CBER/FDA

Peter Marks joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in 2016. Dr. Marks is board certified in internal medicine, hematology, and medical oncology, and is a Fellow of the American College of Physicians. Prior to the FDA, Dr. Marks worked for several years in the pharmaceutical industry on the clinical development of hematology and oncology products prior to returning to academic medicine at Yale University where he led the Adult Leukemia Service and served as Chief Clinical Officer of Smilow Cancer Hospital.

Thomas Wozniewski, PhD, Global Manufacturing and Supply Officer, Takeda

Thomas Wozniewski is Global Manufacturing & Supply Officer of Takeda Pharmaceutical Company Ltd. He was appointed to this role in July 2014. Mr. Wozniewski has focused on globalization, technological and digital transformation and the implementation of a continuous and agile improvement culture within the manufacturing network of more than30 manufacturing sites. Mr. Wozniewski has more than 20 years of experience in the pharmaceutical industry.

To learn more about this event and to register, visit ISPE.org/AM22.

About ISPE

The International Society for Pharmaceutical Engineering (ISPE) is the world’s largest nonprofit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle. The 20,000+ members of ISPE provide solutions to complex pharmaceutical industry challenges through innovation, member and workforce development, technical, regulatory and compliance collaborations in more than 90 countries around the world. Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA. Visit ISPE.org for more information.

Share article on social media or email:

Adding Tezepelumab to Allergen Immunotherapy Reduces Nasal Symptoms in Patients with Cat Allergies


AAAAI Logo

One year after stopping all treatments, the combination of tezepelumab plus immunotherapy resulted in a reduction in expression of a number of genes which control allergic inflammation.

A combination treatment of tezepelumab and allergen immunotherapy for patients with cat allergies resulted in reductions to the nasal allergen challenge (NAC) compared with the treatment of allergen immunotherapy alone. The new research was published in The Journal of Allergy and Clinical Immunology (JACI), an official journal of the American Academy of Allergy, Asthma & Immunology (AAAAI). The trial was conducted by the Immune Tolerance Network and supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.

The study demonstrated that while subcutaneous allergen immunotherapy (SCIT) alone performed better than the placebo after one year of treatment, the effects were no longer present a year after treatment concluded. Patients who received both SCIT and tezepelumab, however, showed a reduction in peak nasal symptoms induced by cat allergen challenge (a key secondary endpoint) one year after treatment was stopped. “We know from prior research that SCIT alone may only be partially effective in some patients, and it needs to be administered for a minimum of three years to induce lasting tolerance,” said Jonathan Corren, MD, first author of the study. “We found that combining tezepelumab plus SCIT resulted in a persistent significant reduction in allergen responsiveness one year after treatment was stopped, indicating that the combination treatment provided a degree of tolerance for patients with cat allergies.”

Researchers conducted the double-blind trial in 121 patients with cat allergies. Patients were randomized to receive SCIT alone, tezepelumab alone, SCIT and tezepelumab combined, or a placebo over 52 weeks, followed by 52 weeks of observation.

In addition to the key finding noted above, combination therapy was also significantly more effective than SCIT alone at week 52. This outcome indicates that there is an additive effect on nasal responsiveness to allergen while patients are actively receiving both treatments.

Serum assessments found that serum concentrations of IL-5 and IL-13 were lower in the combination group compared to SCIT alone, as well as in the tezepelumab alone group. Reductions in cat-specific IgE saw ongoing reductions after week 52 in the combination and tezepelumab groups while the reductions plateaued at week 52 for the SCIT alone group.

Researchers also discovered a number of type 2 gene alterations. Dr. Corren explains, “One year after stopping all treatments, the combination of tezepelumab plus immunotherapy resulted in a reduction in expression of a number of genes which control allergic inflammation. Most important of these were genes which control the production of mast cell mediators, particularly tryptase”.

You can learn more about immunotherapy on the American Academy of Allergy, Asthma & Immunology website, aaaai.org.

The American Academy of Allergy, Asthma & Immunology (AAAAI) is the leading membership organization of more than 7,100 allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic and immunologic diseases. The AAAAI is the go-to resource for patients living with allergies, asthma and immune deficiency disorders. Established in 1943, the AAAAI has more than 7,100 members in the United States, Canada and 72 other countries. The AAAAI’s Find an Allergist/Immunologist service is a trusted resource to help you find a specialist close to home.

Share article on social media or email: